Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

DATE OF RELEASE/EXPIRATION

This activity was released on March 1, 2023 and is valid until March 1, 2024. Requests for credit must be made no later than March 1, 2024.

TARGET AUDIENCE

The educational design of this activity addresses the needs of community-based hematologic oncologists, hematologists, medical oncologists, oncology advanced practice providers (NPs and PAs), oncology nurses, pharmacists, and other clinicians involved in the management of patients with NHL.

STATEMENT OF NEED/PROGRAM OVERVIEW

With many diverse racial and ethnic populations (including American Indian/Alaska Native, Black, and Asian/Pacific Islander patients) experiencing low 10-year relative survival rates related to non-Hodgkin lymphoma (NHL), it is important that all patients receive quality care to improve survival. This includes consideration of clinical trials, which often provide patients access to breakthrough treatments and emerging therapeutic options. However, one of the greatest disparities in cancer care is access to clinical trials and ensuring diverse participation.

Join an expert panel of hematology/oncology specialists and advanced practitioners to discuss the implications of the lack of diversity and inclusion in NHL clinical trials. Panelists will share strategies to communicate with patients about the clinical-trial process, help them decipher eligibility criteria, and identify trials that could provide them with unique and effective treatments for NHL.

Education is also available for your patients with NHL. Help dispel the myths and misconceptions about clinical research and direct your patients to CancerCoachLive.com to access the activity, “Considering a Clinical Trial as Treatment for Your NHL? Key Questions Answered.”

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Amend the misconceptions of clinicians that inhibit the consideration of clinical trials
• Assess patient perceptions on participation in clinical research
• Counsel patients using culturally appropriate skills and furnish patients with clinical-trial education
• Discuss ongoing clinical trials in NHL that represent new and emerging mechanisms of action and outline their eligibility criteria

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

FACULTY AND DISCLOSURE OF CONFLICTS OF INTEREST

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty	Conflicts of Interest
Ashley Leak Bryant, PhD, RN, OCN, FAAN Associate Professor, School of Nursing Assistant Director, Cancer Research Training and Education Coordination The University of North Carolina at Chapel Hill UNC Lineberger Comprehensive Cancer Center	Researcher: Carevive Systems, Inc., Jazz Pharmaceuticals
Enrique Diaz, MD, MSc Associate Professor of Medicine Division of Hematology Oncology Lead, Adult Lymphoma Program Mays Cancer Center UT Health San Antonio	Consultant, Advisor, and Speaker: ADCT, AstraZeneca, Genentech, Incyte/Morphosys, Lilly
Christopher R. Flowers, MD, MS, FASCO Division Head ad interim, Division of Cancer Medicine Chair, Professor, Department of Lymphoma/Myeloma UT MD Anderson Cancer Center	Consultant, Advisor, and Speaker: AbbVie, AstraZeneca, Bayer, BeiGene, Bio Ascend, Bristol Myers Squibb, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/ Janssen, Seagen, Spectrum Stock/stock options private company: Foresight Diagnostics, N Power Researcher: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD Serono, Genentech/Roche, Gilead, Guardant, Iovance, Janssen, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: For additional information about the accreditation of this activity, please visit https://partnersed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.